Folgen
Gøril Eide Flaten
Gøril Eide Flaten
Bestätigte E-Mail-Adresse bei uit.no
Titel
Zitiert von
Zitiert von
Jahr
Gene transfer potential of outer membrane vesicles of Acinetobacter baylyi and effects of stress on vesiculation
S Fulsundar, K Harms, GE Flaten, PJ Johnsen, BA Chopade, KM Nielsen
Applied and environmental microbiology 80 (11), 3469-3483, 2014
2422014
In vitro skin models as a tool in optimization of drug formulation
GE Flaten, Z Palac, A Engesland, J Filipović-Grčić, Ž Vanić, ...
European journal of pharmaceutical sciences 75, 10-24, 2015
2292015
Drug permeability across a phospholipid vesicle based barrier: A novel approach for studying passive diffusion
GE Flaten, AB Dhanikula, K Luthman, M Brandl
European journal of pharmaceutical sciences 27 (1), 80-90, 2006
2242006
Drug permeability profiling using cell-free permeation tools: Overview and applications
P Berben, A Bauer-Brandl, M Brandl, B Faller, GE Flaten, AC Jacobsen, ...
European Journal of Pharmaceutical Sciences 119, 219-233, 2018
1902018
A synthetic antimicrobial peptidomimetic (LTX 109): stereochemical impact on membrane disruption
J Isaksson, BO Brandsdal, M Engqvist, GE Flaten, JSM Svendsen, ...
Journal of medicinal chemistry 54 (16), 5786-5795, 2011
1802011
Current challenges and future perspectives in oral absorption research: An opinion of the UNGAP network
Z Vinarov, B Abrahamsson, P Artursson, H Batchelor, P Berben, ...
Advanced Drug Delivery Reviews 171, 289-331, 2021
992021
Drug permeability across a phospholipid vesicle-based barrier: 2. Characterization of barrier structure, storage stability and stability towards pH changes
GE Flaten, H Bunjes, K Luthman, M Brandl
European journal of pharmaceutical sciences 28 (4), 336-343, 2006
872006
Drug permeability across a phospholipid vesicle-based barrier: 4. The effect of tensides, co-solvents and pH changes on barrier integrity and on drug permeability
GE Flaten, K Luthman, T Vasskog, M Brandl
European journal of pharmaceutical sciences 34 (2-3), 173-180, 2008
652008
In-vitro permeability of poorly water soluble drugs in the phospholipid vesicle-based permeation assay: the influence of nonionic surfactants
SM Fischer, GE Flaten, E Hagesæther, G Fricker, M Brandl
Journal of Pharmacy and Pharmacology 63 (8), 1022-1030, 2011
642011
Synthesis of Cationic Antimicrobial β2,2-Amino Acid Derivatives with Potential for Oral Administration
T Hansen, D Ausbacher, GE Flaten, M Havelkova, MB Strøm
Journal of medicinal chemistry 54 (3), 858-868, 2011
642011
Chitosan in mucoadhesive drug delivery: Focus on local vaginal therapy
T Andersen, S Bleher, GE Flaten, I Tho, S Mattsson, N Škalko-Basnet
Marine drugs 13 (1), 222-236, 2015
632015
Liposomes for (trans)dermal drug delivery: the skin-PVPA as a novel in vitro stratum corneum model in formulation development
Z Palac, A Engesland, GE Flaten, N Škalko-Basnet, J Filipović-Grčić, ...
Journal of liposome research 24 (4), 313-322, 2014
612014
Altered activity and physicochemical properties of short cationic antimicrobial peptides by incorporation of arginine analogues
J Svenson, R Karstad, GE Flaten, BO Brandsdal, M Brandl, JS Svendsen
Molecular pharmaceutics 6 (3), 996-1005, 2009
572009
Drug permeability across a phospholipid vesicle based barrier: 3. Characterization of drug–membrane interactions and the effect of agitation on the barrier integrity and on the …
GE Flaten, M Skar, K Luthman, M Brandl
european journal of pharmaceutical sciences 30 (3-4), 324-332, 2007
562007
New applications of phospholipid vesicle-based permeation assay: permeation model mimicking skin barrier
A Engesland, M Skar, T Hansen, N Škalko-Basnet, GE Flaten
Journal of Pharmaceutical Sciences 102 (5), 1588-1600, 2013
532013
In-vitro permeability screening of melt extrudate formulations containing poorly water-soluble drug compounds using the phospholipid vesicle-based barrier
J Kanzer, I Tho, GE Flaten, M Mägerlein, P Hölig, G Fricker, M Brandl
Journal of Pharmacy and Pharmacology 62 (11), 1591-1598, 2010
512010
Chitosan-Based Nanomedicine to Fight Genital Candida Infections: Chitosomes
T Andersen, E Mishchenko, GE Flaten, JUE Sollid, S Mattsson, I Tho, ...
Marine Drugs 15 (3), 64, 2017
482017
A method to determine the incorporation capacity of camptothecin in liposomes
AM Sætern, GE Flaten, M Brandl
Aaps Pharmscitech 5, 30-37, 2004
482004
Phospholipid vesicle-based permeation assay and EpiSkin® in assessment of drug therapies destined for skin administration
A Engesland, N Škalko-Basnet, GE Flaten
Journal of Pharmaceutical Sciences 104 (3), 1119-1127, 2015
442015
Deformable liposomes for skin therapy with human epidermal growth factor: The effect of liposomal surface charge
S Ternullo, P Basnet, AM Holsæter, GE Flaten, L de Weerd, ...
European Journal of Pharmaceutical Sciences 125, 163-171, 2018
422018
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20